November is ‘Intern Spotlight Month’ here at Health Action International (HAI), when we shine a light on the interns who make tremendous contributions to our team and the work we do with their fresh perspectives, new ideas, intellect and vivacious spirit. Each week throughout the month of November, we’ll introduce you to one of our interns from the past year who’ll explain the research they conducted during their internship,
Clinical trials are key to determining the safety and efficacy of medicines. But to do so, trials must be robust and ethical—and their full results must be reported publicly. Unfortunately, many trials are not meeting this criteria. More and more are being off-shored to developing countries where they can be conducted more cheaply and with questionable ethical standards.
Health Action International is, once again, pleased to be in Geneva this week attending the 69th World Health Assembly. If you will be there, too, please plan on attending a side event on ‘Achieving Affordable Access to Health Technologies’, which we are co-organising with the Medicines for Malaria Venture and Oxfam.
The event will be held on Tuesday,
Every year, snakebite kills 125,000 people around the world and gravely injures 2.7 million more. For the first time at a World Health Assembly (WHA) side event, leading venom and snakebite experts, government representatives and medicine policy experts will discuss global challenges, initiatives and strategies to reduce death and disability from snakebite envenoming—one of the world’s most tragic and neglected tropical diseases.
by TIM REED
With a heavy heart, I write with news of the passing HAI founder, life member of the HAI European network, and our dear friend, Andrew Herxheimer, who passed away on Sunday, 21 February, at the age of 90.
Andrew was a clinical pharmacologist by training—and an access to medicines activist at heart.
by MOLLY LEPESKA
An ACCISS Study Review of the global insulin market, called ‘Constraints and Challenges in Access to Insulin: A Global Perspective, was published Friday in The Lancet Diabetes & Endocrinology. Co-authored by ACCISS Study leaders, David Beran, Marg Ewen and Richard Laing, the Review describes why insulin is still unattainable for approximately half of all people who need it.